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Hsp90 is a cytosolicmolecular chaperonewhose paralog inmitochondria, TRAP1, protects cells from
oxidative stress. The recent study in Cell by Kang et al. [1] now identifies the molecular components
of the proapoptotic network regulated by TRAP1, that includes Hsp90. Targeting Hsp90/TRAP1
inhibitors to mitochondria induces rapid tumor cell-specific apoptosis.The family of mammalian heat shock
protein (Hsp) 90 molecular chaper-
ones includes the cytosolic Hsp90a
(stress-inducible) and b (constitutive)
isoforms, the endoplasmic reticulum
(ER)-restricted glucose-regulated pro-
tein (Grp) 94, and the mitochondri-
ally localized paralog TRAP1. Among
the family, the function(s) of cytosolic
Hsp90 have been most intensively in-
vestigated. These include regulating
the stability and activity of between
one and two hundred cytosolic and
nuclear ‘‘client’’ proteins among which
are numerous protein kinases, tran-
scription factors, and other proteins
that serve as nodal points which in-
tegrate cellular responses to multiple
extracellular signals. Thus, cytosolic
Hsp90 function is a key component
underlying maintenance of cellular ho-
meostasis in the face of environmental
fluctuation. This is particularly impor-
tant to cancer cells, which frequently
face both noxious extracellular (e.g.,
hypoxia) and intracellular (e.g., protein
misfolding) environments.
Hsp90 is a conformationally flexible
protein that associates with a distinct
set of cochaperones depending on
ATP or ADP occupancy of an amino-
terminal binding pocket. Nucleotide
exchange and ATP hydrolysis by
Hsp90 itself, with the assistance of co-
chaperones, drive the Hsp90 chap-
erone machine to bind, chaperone,
and release client proteins. Nucleo-
tide-dependent cycling of the cyto-
solic Hsp90 chaperone machine is
critical to its function. Pharmacologic
inhibitors of Hsp90’s nucleotide bind-
ing prevent chaperone cycling and1204 Chemistry & Biology 14, Novembergenerally promote the proteasome-
mediated degradation of client pro-
teins [2]. Because of the diverse func-
tions of its numerous client proteins,
Hsp90 inhibition is predicted to impact
all of the six hallmarks of cancer, as
defined by Hanahan and Weinberg
[3], and indeed these drugs have dem-
onstrated anticancer activity in both
diverse animal xenograft models and
in several human clinical trials [4].
Much less is known about the func-
tion(s) of Grp94 and TRAP1. Unlike
cytosolic Hsp90, neither the ER nor
the mitochondrial paralog is known to
interact with cochaperones nor have
any of their ‘‘client’’ proteins been con-
vincingly identified. Like Hsp90, both
proteins utilize their N-terminal do-
mains to bind and hydrolyze ATP and
both proteins interact with Hsp90 in-
hibitors [5–7]. Although Grp94 and
TRAP1bothbindN-terminal smallmol-
ecule inhibitors with an affinity similar
to that of cytosolic Hsp90, no signifi-
cant sequellae of drug binding to these
proteins have been identified. Re-
cently, several reports have implicated
TRAP1 in protecting cells from mito-
chondria-mediated apoptosis induced
by oxidative stress [8–10]. Inactivation
or depletion of TRAP1 may play a role
in neurodegenerative diseases of the
central nervous system [9].
In general, small molecule inhibitors
of Hsp90 induce growth arrest. In cer-
tain tumor-specific instances, induc-
tion of apoptosis has been observed
[11]. In contrast, Altieri and colleagues
previously reported that a peptide-
based Hsp90 inhibitor, shepherdin,
caused rapid and extensive mitochon-2007 ª2007 Elsevier Ltd All rights reserveddria-dependent apoptosis in all tumor
types examined [12]. The study by
Kang et al., published in the October
19, 2007, issue of Cell, serves to ex-
tend this initial observation and to of-
fer an explanation for the apparent
discrepancy between the cellular re-
sponse to small molecule and pep-
tide-based Hsp90 inhibitors [1]. Kang
et al. also propose that mitochondrial
homeostasis is differentially regulated
in tumor versus normal cells, in part
due to elevated expression in mito-
chondria not only of TRAP1 but also
of Hsp90 itself.
Unlike the small molecule Hsp90
inhibitors, the peptide-based inhibitor
shepherdin by itself is unable to cross
the plasma membrane. In order to cir-
cumvent this problem, Altieri and col-
leagues included thehelix III homeodo-
main cell-penetrating sequence from
Antennapedia in the shepherdin pep-
tide. The current study by Kang et al.
reports that the Antennapedia se-
quence not only facilitates intracellular
uptake of shepherdin but unexpect-
edly serves to target the peptide to
mitochondria, where its accumulation
results in membrane depolarization
and cytochrome c release. In contrast,
while small molecule Hsp90 inhibitors
readily cross the plasma membrane,
they remain primarily cytosolic and
neither localize to mitochondria nor
promote mitochondrial membrane
depolarization. This differential intra-
cellular localization appears to be key
to the proapoptotic effects of shep-
herdin, since removing the Antennape-
dia sequence from shepherdin abro-
gates its ability to affect the membrane
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Further, coupling the prototypical
Hsp90 inhibitor geldanamycin to the
Antennapedia sequence allows the
drug to efficiently penetrate the mito-
chondrial membrane and to promote
depolarization and cytochrome c re-
lease similar to shepherdin. Thus, the
discrepant cellular activity of shepher-
din and the smallmoleculeHsp90 inhib-
itors appears due to their differential
ability to penetrate into mitochondria.
In their original study, Altieri and col-
leagues demonstrated that the apo-
ptosis-inducing effects of shepherdin
were limited to transformed cells and
that the viability of normal cells was
unaffected by this Hsp90 inhibitor
[12]. In the current article in Cell [1],
Kang et al. provide one rationale for
this observation. They report that mito-
chondria isolated from a panel of
tumor cell lines express markedly
elevated levels of TRAP1 and, more
surprisingly, of Hsp90 itself. Examina-
tion of mitochondria isolated from
a number of nontransformed fibroblast
cell lines and from a panel of normal
tissues reveals much reduced expres-
sion of TRAP1 and little to no detect-
able Hsp90. Interestingly, the sole
exceptions are mitochondria isolated
from mouse brain and testis, in which
Hsp90 expression is readily observed.
Is there a common factor that may link
these observations? Because of their
dependence on glycolysis and fre-
quent exposure to fluctuating oxygen
levels, tumor cells exist in a general
state of oxidative stress. Because
they are both subject to high energy
demands, testis and brain rely heavily
on aerobic glycolysis to generate large
amounts of ATP, and they are also
prone to oxidative stress [13, 14].
Overexpression of TRAP1 and Hsp90
may serve to buffer mitochondrial
(and in the case of Hsp90 also cyto-
solic) proteins from direct damage
caused by exposure to prolonged
oxidative stress. Indeed, it is possible
that appearanceofHsp90 inmitochon-
dria of tumor cells is merely a matter
of degree—because environmentally
stressed tumor cells contain signifi-
cantly more of the chaperone than do
nontransformed cells, a proportionally
greater amount of Hsp90 may be de-
tectable in tumor mitochondria.CFigure 1. Hsp90 Inhibitors Trigger Mitochondrial Membrane Depolarization-
Dependent Apoptosis in Tumor Cells
Based on the recent paper by Kang et al. [1], Hsp90 is overexpressed in mitochondria of tumor
cells (as well as brain and testis) and associates spontaneously with the immunophilin Cyclophilin
D (CypD). In the presence of Hsp90 inhibitor, which displaces ATP from Hsp90, CypD (still bound
to Hsp90) becomes active and promotesmitochondrial membrane depolarization. This causes cy-
tochrome c to be released into the cytosol, triggering the intrinsic apoptotic pathway [15]. Surpris-
ingly, even though CypD is also highly expressed in neuronal mitochondria, as is Hsp90, apoptosis
induced by Hsp90 inhibitors appears to be tumor-specific.Why does the mitochondrial tar-
geting of Hsp90 inhibitors promote
apoptosis? Kang et al. implicate the
mitochondrially localized immunophi-
lin Cyclophilin D (CypD) in this phe-
nomenon (see Figure 1). They show
that CypD, a mediator of oxidative
stress-induced cell death [15], associ-
ates with both Hsp90 and TRAP1 (al-
though apparently in separate com-
plexes) and that the CypD inhibitor
Cyclosporin A (CsA) abrogates Hsp90
inhibitor-induced membrane depolar-
ization and cytochrome c release. CsA
prevents association of both Hsp90
and TRAP1 with CypD, suggesting
that this associationmay be necessary
for CypD activity. In support of this hy-
pothesis, Hsp90 inhibitors do not dis-
sociate CypD from either Hsp90 or
TRAP1. How can we reconcile the ob-
servation that both Hsp90 and TRAP1
spontaneously associate with CypD,
yet CypD activity is only apparent fol-
lowing Hsp90 inhibition? One possibil-
ity is that the nucleotide state of mito-
chondrial Hsp90 (and TRAP1) may be
a determining factor. When associated
with the ATP-bound conformation ofhemistry & Biology 14, November 2007 ª2either chaperone, the activity of CypD
is suppressed. However when the
ATP concentration falls to dangerously
low levels or when the Hsp90/TRAP1
nucleotide binding site is occupied by
an inhibitor, conformation of the chap-
erone/CypD complex alters to permit
CypD activity. CypD may also require
continued association with Hsp90/
TRAP1 to deliver it to an appropriate
location or protein to be modified,
since Hsp90 inhibitor treatment does
not dissociate CypD from Hsp90/
TRAP1. Since CsA inhibits CypD-
mediated membrane depolarization,
it is likely that this process requires
the immunophilin’s peptidylprolyl
isomerase activity (inhibited by CsA),
which may also be necessary for as-
sociation of the immunophilin with
Hsp90/TRAP1. A contribution of oxi-
dative stress to elevated chaperone
expression cannot be overlooked. Ce-
rtainly, some of the increased Hsp90/
TRAP1 in tumor cell mitochondria
may be protecting key mitochondrial
proteins from oxidative damage. Is as-
sociation of either Hsp90 or TRAP1
with CypD affected by the necessity007 Elsevier Ltd All rights reserved 1205
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tochondrial proteins? If such a mito-
chondrial ATP- or protein damage-
sensing ‘‘suicide’’ mechanism exists,
can it be exploited to preferentially kill
cancer cells, as suggested by Kang
et al.?
A growing body of evidence, includ-
ing the Kang et al. study, proposes
a role for TRAP1 in cellular protection
from oxidative stress-induced apop-
tosis [1, 8–10]. The identification of
CypD as a TRAP1-interacting protein
provides an attractive mechanism to
explain these observations. As all pro-
vocative studies should, the paper
by Kang et al. raises many additional
questions for future exploration. Does
localization of Hsp90 to mitochondria
depend on oxidative stress and does
it contribute to the maintenance of
mitochondrial homeostasis under ex-
treme conditions? Perhaps this possi-
bility might be explored by determining
the effect of reducing agents or free
radical scavengers on Hsp90 localiza-
tion (and TRAP1 expression). Why are
both Hsp90 and TRAP1 necessary to
promote mitochondrial homeostasis
in tumor cells if they both serve to reg-
ulate the same apoptosis transducer
(CypD)? How is Hsp90 targeted to mi-
tochondria of tumor cells? Is it merely
a correlative result of cellular over-
expression of the chaperone or is a
unique process (e.g., posttranslational
modification of Hsp90) responsible?
Isolation and characterization of the
mitochondrial pool of Hsp90 in com-
parison with the cytosolic pool might
address this question. Is mitochondrial
homeostasis differentially susceptible
to chaperone interference in certain
tumor types? Small molecule Hsp90
inhibitors cause marked cytochrome
c-dependent apoptosis in small cell
lung cancer and in other neuroendo-
crine tumors in which the retinoblas-
toma protein is defective [11]. Do these1206 Chemistry & Biology 14, Novembedrugs penetrate the mitochondria in
these tumors? Interestingly, cytosolic
Hsp90 negatively regulates Apaf-1
oligomerization (relieved by Hsp90 in-
hibition), which is mediated by cyto-
chrome c released from mitochondria
and is required for activation of pro-
caspase-9 [16]. Thus, in sensitive cells
Hsp90 inhibitors may impact the in-
trinsic apoptotic pathway at multiple
points.
Lastly, it is very important to under-
stand why neither shepherdin nor
Antennapedia-coupled geldanamycin
seem to cause membrane depolariza-
tion and cytochrome c release in brain
mitochondrial preparations (as de-
scribed in the Kang et al. study). Mito-
chondrial CypD is found in most if not
all normal tissues, and in fact the im-
munophilin is abundantly expressed
in neuronal mitochondria [17]. Indeed,
inhibition of neuronal CypD has been
suggested as an approach to prevent
dopaminergic neurodegeneration as-
sociated with Parkinson disease (PD)
[18]. Since TRAP1 inactivation has re-
cently been suggested to be adetermi-
nant of PD pathogenesis [9], it will be
essential to thoroughly eliminate the
possibility of inadvertent activation of
neuronal CypD when considering the
future therapeutic benefit of targeting
Hsp90 inhibitors to mitochondria. To
this end, it is very important to under-
stand why tumor cell CypD appears
to be preferentially sensitive to activa-
tion by Hsp90 inhibitors directed to
this subcellular compartment.
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